Don M Benson
Affiliation: The Ohio State University
Benson D, Bakan C, Zhang S, Collins S, Liang J, Srivastava S, et al
. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118:6387-91 pubmed publisher
..These mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM. ..
Benson D, Cohen A, Jagannath S, Munshi N, Spitzer G, Hofmeister C, et al
. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2015;21:4055-61 pubmed publisher
..This trial was registered at www.clinicaltrials.gov (reference: NCT01217203). ..
Benson D, Panzner K, Hamadani M, Hofmeister C, Bakan C, Smith M, et al
. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leuk Lymphoma. 2010;51:243-51 pubmed publisher
..Our data extrapolate on prior work and expand on ongoing controversies about optimal induction regimens for patients with MM planned for subsequent HDC/SCT and optimal sequencing of therapies. ..